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Abstract
Background: Genome wide association studies (GWAS) have identified several SNPs associated with colorectal cancer (CRC)
susceptibility. Vitamin D is also inversely associated with CRC risk.
Methods: We examined main and joint effects of previously GWAS identified genetic markers of CRC and plasma 25-
hydroxyvitamin D (25(OH)D) on CRC risk in three prospective cohorts: the Nurses’ Health Study (NHS), the Health
Professionals Follow-up Study (HPFS), and the Physicians’ Health Study (PHS). We included 1895 CRC cases and 2806
controls with genomic DNA. We calculated odds ratios and 95% confidence intervals for CRC associated with additive
genetic risk scores (GRSs) comprised of all CRC SNPs and subsets of these SNPs based on proximity to regions of increased
vitamin D receptor binding to vitamin D response elements (VDREs), based on published ChiP-seq data. Among a subset of
subjects with additional prediagnostic 25(OH)D we tested multiplicative interactions between plasma 25(OH)D and GRS’s.
We used fixed effects models to meta-analyze the three cohorts.
Results: The per allele multivariate OR was 1.12 (95% CI, 1.06–1.19) for GRS-proximalVDRE; and 1.10 (95% CI, 1.06–1.14) for
GRS-nonproxVDRE. The lowest quartile of plasma 25(OH)D compared with the highest, had a multivariate OR of 0.63 (95%
CI, 0.48–0.82) for CRC. We did not observe any significant interactions between any GRSs and plasma 25(OH)D.
Conclusions: We did not observe evidence for the modification of genetic susceptibility for CRC according to vitamin D
status, or evidence that the effect of common CRC risk alleles differed according to their proximity to putative VDR binding
sites.
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Introduction
Both inherited and modifiable risk factors have been identified
for colorectal cancer (CRC). To date, genome wide association
studies (GWAS) have identified 32 SNPs at 23 independent loci
associated with CRC [1–16]. A substantial body of evidence also
demonstrates an inverse association between vitamin D status and
CRC [17–24]. Nonetheless, data examining the potential interac-
tion between genetic susceptibility to CRC and an environmental
factor such as vitamin D status are lacking.
There are plausible mechanisms by which genetic susceptibility
to CRC may vary according to vitamin D status. First, one of the
primary modes of action of vitamin D is via influence of gene
transcription by binding of the active form 1,25-dihydroxy-vitamin
D (1,25(OH)2D3) to the nuclear vitamin D receptor (VDR) [25]. A
prior study utilizing chromatin immunoprecipitation with mas-
sively parallel sequencing (ChIP-seq) to identify vitamin D
receptor (VDR) protein– DNA binding interactions observed that
VDR binding sites were significantly enriched near autoimmune
and cancer associated genes [26], including 3 previously identified
CRC-associated SNPs. Second, although our understanding of the
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e92212functional implications of many CRC-associated SNPs is limited, it
is possible that some of these loci may be associated mechanis-
tically with pathways also influenced by vitamin D.
Thus, we examined the joint effects of genetic markers of
CRC previously identified by GWAS and plasma 25(OH)D on
CRC risk in three prospective cohorts: the Nurses’ Health Study
(NHS), the Health Professionals Follow-up Study (HPFS), and
the Physicians’ Health Study (PHS). We also specifically
explored the possibility that vitamin D status may differentially
influence risk of CRC according to genetic variants proximal to
regions of VDR binding demonstrated in functional ChIP-seq
studies.
Methods
Study Population
Our study included three case-control studies of CRC nested
within the Nurses’ Health Study (NHS), the Health Professionals
Follow-up Study (HPFS) and the Physicians’ Health Study
(PHS). The NHS was established in 1976 when 121,700 US
female registered nurses aged 30 to 55 years returned mailed
questionnaires on risk factors for cancer and cardiovascular
disease [27,28]. The HPFS was established in 1986 when 51,529
male health professionals aged 40 to 75 years responded to a
similar questionnaire [29]. In both cohorts, participants have
returned questionnaires every 2 years to update information
with response rates exceeding 90% [27,28]. In 1989-90, 32,826
NHS participants and in 1993-95, 18,018 HPFS participants
returned a blood specimen on ice packs. In 2001–04, 29,684
women in NHS and 13,956 men in HPFS who had not
previously provided a blood specimen mailed in a ‘swish-and-
spit’ sample of buccal cells. On receipt, blood and buccal cells
were centrifuged, aliquoted, and stored at 270uC [30]. The
Physicians’ Health Study was a randomized, double-blind,
placebo-controlled trial of aspirin and beta-carotene for the
primary prevention of cancer and cardiovascular disease among
22,071 U.S. male physicians ages 40 to 84 years enrolled in
1982 [31]. Participants with a prior diagnosis of heart disease,
cancer (except nonmelanoma skin cancer), renal or liver disease,
peptic ulcer, or gout or used vitamin A or beta-carotene
supplements, were excluded. Between 1982 and 1984, 14,916
men (more than 70% of participants) returned blood samples by
mail which were divided into aliquots and stored at 282uC
(later, at 2140uC) [32]. This study was approved by the Human
Subjects Committee at Brigham and Women’s Hospital and the
Harvard School of Public Health in Boston, MA, USA. All
participants provided informed consent.
In all three cohorts, incident cases of CRC were identified
by follow-up questionnaires and confirmed by medical records
review or through mortality follow-up. In each cohort, up to 3
controls were randomly selected from those who were alive and
free of cancer at the time of case ascertainment. In NHS and
HPFS, controls were matched to each case on ethnicity, year of
birth and month/year of blood or buccal sampling [30]; in
PHS, controls were additionally matched on smoking status
[32].
Laboratory Assessment
We previously measured plasma levels of 25(OH)D through a
radioimmunosorbent assay in the laboratory of Dr. Bruce W.
Hollis (Medical University of South Carolina, Charleston, SC).
The median intra-assay coefficient of variation from blinded
quality-control samples was 11.8% in NHS, 10.1% in HPFS, and
13.8% in PHS. Cases and their controls were analyzed in the same
batch, and laboratory personnel were blinded to case, control, and
quality-control status [23,32,33].
Genotyping
Genomic DNA was extracted from blood samples (HPFS, NHS,
PHS) and buccal cells (NHS, HPFS) using conventional methods.
We used the TaqMan Open Array SNP genotyping platform
(Biotrove, Woburn, MA) with 384-well format TaqMan assays to
genotype the following CRC-associated variants identified from
previous GWAS: rs6691170, rs6687758, rs10936599, rs16892766,
rs6983267, rs10795668, rs3802842, rs10505477, rs7014346,
rs7136702, rs11169552, rs4444235, rs4779584, rs9929218,
rs4939827, rs10411210, rs961253, rs4925386 [4,8-10,12,15,16].
TaqMan primers and probes were designed using Primer Express
Oligo Design software v2.0 (ABI PRISM). Primers, probes, and
conditions for genotyping assays are available upon request. We
genotyped rs2151512 on Taqman as a surrogate for rs4925386
(linkage disequilibrium r
2 1.0 in the HapMap CEU population)
since genotyping by Taqman for rs4925386 on chromosome
20q13.33 was not successful.A subset of participants (954 cases and
1328 controls) had blood genomic DNA successfully genotyped
using Illumina HumanOmniExpress. Missing SNP data was
imputed to HapMap II release 22 using MACH [34]. All
genotyping underwent standard quality control including concor-
dance checks for blinded and unblinded duplicates and examina-
tion of sample and SNP call rates. The call rate was .97% for all
samples and .98% for all SNPs.
Statistical Analysis
We included a total of 1895 CRC cases and 2806 controls with
genotype information assembled from NHS, HPFS, and PHS for
our GRS. Within each cohort, we calculated allelic odds ratios and
95% confidence intervals for CRC associated with each SNP and
for genetic risk scores (GRSs). The GRS is an allelic scoring system
incorporating each of the specified risk alleles associated with CRC
based on prior GWAS to assign a single quantitative index of
genetic risk to each subject. Our GRS assumes an additive allelic
effect with carriage of an increasing number of copies of each risk
variant.
We constructed a GRS comprised of 18 Taqman CRC
susceptibility SNPs (GRS-18). We also examined GRSs comprised
of a subset of these SNPs based upon the 10 SNPs examined in. a
ChiP-seq analysis (GRS-10) conducted by Ramagopalan et al. In
this analysis, 3 CRC-associated SNPs were proximal (within
150 kb on either side of main disease-associated SNP) to increased
VDR binding (vitamin D response elements (VDRE)) (GRS-
proximalVDRE), and 7 SNPs were not proximal to areas of
increased VDR binding (GRS-nonproxVDRE) [26]. Among the
2,282 subset of individuals with additional GWAS data, we
created a GRS comprised of 31 CRC associated SNPs from
GWAS (GRS-31). We also calculated GRSs using the effect
estimates and standard errors for these same SNPs from large scale
GWAS [35] and tested for differences in the GRS-proximalVDRE
and GRS-nonproxVDRE.
For analyses of the joint effect of plasma 25(OH)D and GRS-18,
we included the 881 cases and 1566 controls in NHS, HPFS, and
PHS who also had previously measured 25(OH)D prior to CRC
diagnosis [23,32]. This was repeated for the joint effects of GRS-
31 and pre-CRC 25(OH)D levels among the 672 cases and 909
controls with both GWAS data and vitamin D levels. We
calculated odds ratios and 95% confidence intervals for CRC
associated with each 1 ng/mL increase in 25(OH)D; high versus
low vitamin D according to a threshold level of 25(OH)D
associated with lower CRC risk ($32 ng/mL); and quartiles of
Joint Effect of CRC Loci and 25(OH)D on CRC Risk
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PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e9221225(OH)D [32]. We tested for multiplicative interactions between
GRSs and vitamin D using a product term in the model and
assessing its significance by the Wald method.
We adjusted our genetic analyses for age at sample collection,
race, cohort, and type of sample (blood or cheek). Analyses which
also incorporated plasma 25(OH)D additionally adjusted for
season of blood draw and 25(OH)D analysis batch. We also used
multivariate models which included additional CRC risk factors,
including regular aspirin use (yes or no), body mass index (BMI; in
tertiles), physical activity (in tertiles), history of CRC in a parent or
sibling (yes or no), smoking status (never, former or current
smoker), alcohol consumption (0–4.9, 5–9.9, 10–14.9 or $ 15.0 g
per day), and consumption of beef, pork or lamb as a main dish (0–
3 times per month, once a week, 2–4 times per week or $5 times
per week). In NHS and HPFS we also included regular non-
steroidal anti-inflammatory drugs (NSAIDs) use (yes or no) and
energy-adjusted calcium and folate intake (in tertiles). Study
specific estimates were meta-analyzed to determine a combined
OR and 95% CI using inverse variance weights [36]. Fixed effect
model estimates were used as all tests of heterogeneity were non-
significant (p.0.05).
Results
Our analysis included 1895 CRC cases and 2806 controls
assembled from the three cohorts. Table 1 summarizes the
baseline characteristics of each cohort. The direction and
magnitude of our individual SNP effect estimates were comparable
to those of the original reports as well as those observed in the
Genetics and Epidemiology of Colorectal Cancer Consortium
(GECCO) and Colon Cancer Family Registry (CCFR). GECCO/
CCFR encompasses 13 studies, including NHS, HPFS, and PHS
with genetic information on a total of 10,061 cases and 12,768
controls (Table 2).
The additive GRSs comprised of the CRC risk alleles yielded
effect estimates for CRC within our three cohorts that were
comparable with those derived from all 13 cohorts encompassed
by GECCO and CCFR (Table 3). We also compared the
estimates obtained from models with the GRS-proximalVDRE
and GRS-nonproximalVDRE scores alone with models contain-
ing both GRSs (conditional models) and did not observe a material
difference. There was no significant difference between a GRS-
VDR (multivariate OR, 1.12; 95% CI 1.06, 1.19), and a GRS-
nonproximalVDRE (multivariate OR, 1.10; 95% CI 1.06, 1.14)
(p-heterogeneity = 0.52).
Consistent with our prior reports [23,32], we observed an
inverse association between 25(OH)D and CRC in a meta-
analysis of results from the three cohorts (Table 4). Compared
with individuals in the lowest quartile of 25(OH)D, men and
women in the highest quartile had a multivariate OR for CRC
of 0.63 (95% CI 0.48–0.82; p-trend,0.001), and for those with
higher levels of 25(OH)D ($ 32 ng/mL) compared with lower
levels, the multivariate OR was 0.79 (95% CI 0.65–0.98;
p=0.03).
Tests of multiplicative interactions between continuous GRSs
and continuous 25(OH)D did not yield statistically significant
results, nor did tests of multiplicative interactions between
GRSs and vitamin D categorized by a threshold level of
32 ng/mL. Likewise, the risk estimates associated with GRS31
did not vary according to quartile of vitamin D (phet=0.98)
(Figure 1).
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There is substantial evidence supporting an inverse association
between circulating 25(OH)D and CRC risk; meta-analyses and
systematic reviews have observed a 50% lower risk of CRC
comparing extreme quintiles of 25(OH)D [21,24]. Several
mechanisms have been hypothesized to underlie this association,
some of which may be shared by pathways associated with the
putative functional consequences of CRC susceptibility SNPs
proximal to VDR-DNA binding sites. In addition, vitamin D
signaling occurs through binding of the active form 1,25(OH)D to
nuclear vitamin D receptor (VDR) along specific genomic
sequences known as vitamin D response elements (VDREs),)
which act to activate or repress gene transcription [25]. In our
study of 1895 CRC cases and 2806 controls nested within three
prospective cohorts, we did not observe statistically significant
evidence for interaction between CRC genetic markers, including
the 3 CRC SNPs identified in a prior CHiP-seq analysis as being
adjacent to VDR-DNA binding sites, and plasma 25(OH)D on
CRC risk, despite observing an increased risk for CRC associated
with GRSs and an inverse association between circulating
25(OH)D levels and CRC. [26].
The lack of a significant interaction between 25(OH)D and
genetic susceptibility to CRC may have several explanations. First,
pathways associated with CRC susceptibility loci may in fact be
distinct or overlap minimally with mechanisms associated with
vitamin D. Second, our GRS and single measures of plasma
25(OH)D measures may be relatively insensitive or incomplete
markers of relevant biological pathways shared by genetic
susceptibility and vitamin D. Third, we constructed GRSs
informed by the results of a functional study by Ramagopalan et
al. that applied ChiP-seq in lymphoblastoid cells treated with
calcitriol for 36 hours to demonstrate subsequent differential
association of vitamin D receptor binding with three specific CRC
susceptibility loci [26]. However, a separate study utilizing ChIP-
Seq in monocytes treated with calcitriol for 40 minutes found only
18% of calcitriol-stimulated VDR-binding sites common to those
observed in Ramagopalan et al. [37,38]. These results suggest that
VDR target gene regulation may differ according to cell type and/
or duration of vitamin D exposure which may be difficult to assess
using circulating measures of 25(OH)D.
Our study has several strengths. First, the availability of both
genetic information and prediagnostic measures of plasma
25(OH)D in our three cohorts permitted, to our knowledge, the
Table 3. Comparison of GRS-31, GRS-18, GRS-10, GRS-proximalVDR and GRS-nonproxVDR.
n (cases/controls)
GRSproximalVDR
a
OR (95% CI)
GRSnonproxVDR
b
OR (95% CI)
GRS-10
x OR
(95% CI)
GRS-18
d OR
(95% CI)
GRS-31
e OR
(95% CI)
NHS 2358 (922/1436) 1.10 (1.01, 1.20) 1.13 (1.07, 1.19) 1.12 (1.07, 1.17) 1.07 (1.04, 1.10) 1.05 (1.02, 1.09)
HPFS 1457 (586/871) 1.13 (1.01, 1.26) 1.08 (1.01, 1.15) 1.09(1.03, 1.16) 1.05 (1.01–1.09) 1.04 (0.98, 1.10)
PHS 886 (387/499) 1.15 (1.01, 1.31) 1.07 (0.98, 1.17) 1.09 (1.01, 1.18) 1.07 (1.02–1.12) 1.05 (1.00, 1.10)
Meta analysis 4701 (1895/2806) 1.12 (1.06, 1.19) 1.10 (1.06, 1.14) 1.10 (1.07, 1.14) 1.06 (1.04–1.09) 1.05 (1.02, 1.08)
GECCO 22829 (10061/12768) 1.11 (1.09, 1.14) 1.09 (1.07, 1.11) 1.10 (1.08, 1.11) 1.08 (1.07, 1.09) 1.08 (1.07, 1.09)
aGRS-proximalVDR: additive genetic risk score used to estimate a per allele OR and 95% CI. Includes SNPs; rs3802842, rs4939827, rs10411210.
bGRS-nonproxVDR: additive genetic risk score used to estimate a per allele OR and 95% CI. Includes SNPs; rs6983267, rs16892766, rs10795668, rs4444235, rs4779584,
rs9929218, rs961253.
xGRS-10: additive genetic risk score used to estimate a per allele OR and 95% CI. Includes SNPs; rs3802842, rs4939827, rs10411210, rs6983267, rs16892766, rs10795668,
rs4444235, rs4779584, rs9929218, rs961253.
dGRS-18: additive genetic risk score used to estimate a per allele OR and 95% CI. Includes SNPs; rs3802842, rs4939827, rs10411210, rs6983267, rs16892766, rs10795668,
rs4444235, rs4779584, rs9929218, rs961253, rs6691170, rs6687758, rs10936599, rs10505477, rs7014346, rs7136702, rs11169552, rs2151512.
eGRS-31: additive genetic risk score used to estimate a per allele OR and 95% CI based upon the subset of cases and controls with GWAS data (394 cases/772 controls in
NHS; 228 cases/222 controls in HPFS; 332 cases/332 controls in PHS). Includes SNPs; rs3802842, rs4939827, rs10411210, rs6983267, rs16892766, rs10795668, rs4444235,
rs4779584, rs9929218, rs961253, rs6691170, rs6687758, rs10936599, rs7136702, rs11169552, rs4925386, rs10911251, rs11903757, rs647161, rs1321311, rs719725,
rs3824999, rs3217810, rs3217901, rs10774214, rs59336, rs1957636, rs11632715, rs16969681, rs2423279, rs4813802.
doi:10.1371/journal.pone.0092212.t003
Table 4. Risk of colorectal cancer associated with circulating 25(OH)D within NHS, HPFS and PHS.
NHS HPFS PHS Meta-analysis
N (case/control) 352/665 277/535 252/366 881/1566
Continuous 25(OH)D 0.98 (0.97, 1.00) 0.99 (0.97, 1.01) 1.01 (0.99, 1.03) 0.99 (0.98, 1.00)
High vitamin D ($ 32 ng/ml) 0.76 (0.54, 1.08) 0.77 (0.56, 1.05) 0.91 (0.59, 1.41) 0.79 (0.65, 0.98)
Quartile 1 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Quartile 2 0.77 (0.53, 1.12) 0.90 (0.60, 1.35) 0.70 (0.41, 1.19) 0.80 (0.62, 1.02)
Quartile 3 0.58 (0.39, 0.87) 0.64 (0.41, 0.99) 0.91 (0.54, 1.52) 0.67 (0.52, 0.86)
Quartile 4 0.57 (0.38, 0.87) 0.67 (0.42, 1.05) 0.67 (0.39, 1.17) 0.63 (0.48, 0.82)
doi:10.1371/journal.pone.0092212.t004
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integrated biomarker of an environmental determinant of CRC
risk. Second, our reasonably large sample size provided individual
SNP and GRS associations that were similar in the direction and
magnitude with estimates from larger cohorts, including the
GECCO and CCFR consortium. We acknowledge limitations of
our study, including a single measurement of 25(OH)D which may
not reflect long-term vitamin D status or the tissue-specific effects
of vitamin D. We also had a more limited sample size of
participants with both genetic information and measured levels of
plasma 25(OH)D.
In summary, in this large study of CRC cases and controls
characterized for genetic susceptibility to CRC with prediagnostic
measurements of 25(OH)D levels, we did not observe evidence for
the modification of genetic susceptibility for CRC according to
vitamin D status.
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